India’s pharmaceutical exports demonstrated significant growth in the first quarter of the financial year 2027, increasing by 6.8 per cent compared to the previous year’s performance. Namit Joshi, Chairperson of Pharmexcil, noted that this development occurred despite several geopolitical challenges faced by the industry, including disturbances in West Asia. Joshi highlighted that the latest figures showcase the resilience of Indian exports.

Joshi remarked that the performance during the first quarter of 2026-2027 was particularly noteworthy, given that the annual growth in the preceding year only reached a modest 2.13 per cent. He emphasised the strong turnaround in performance, marking a positive trend amidst turbulent global conditions.

The growth trajectory strengthened even further in June 2023, with exports increasing by 7.3 per cent. Joshi referred to this month as a particularly successful period, indicating that June’s growth rates were comparable to India’s national GDP growth of 7.8 per cent. Such numbers reflect a robust export performance amidst ongoing international uncertainties.

Resilience Amidst Geopolitical Challenges

Joshi attributed the strength of India’s pharmaceutical exports and domestic consumption to a combination of factors, particularly the resilience shown by the sector despite geopolitical challenges. He specifically mentioned the ongoing crises in the Middle East and West Asia as significant adverse influences. However, he pointed out that these factors have not hampered the growth of India’s export capabilities.

Highlighting the impact on GDP, Joshi stated that the resilience shown by the Indian pharmaceutical sector is a vital contributor to the country’s overall economic strength. Such performance not only indicates growth in exports but also suggests the robust nature of domestic consumption amid global economic uncertainties.

In terms of future expectations, Joshi expressed cautious optimism regarding India’s reliance on China within the pharmaceutical supply chain. He noted that while immediate reduction in this dependency is unlikely, a shift towards greater collaboration is anticipated over time. This, he believes, could signal a move from competitive dynamics towards cooperative engagements.

Strategies for Enhanced Self-Reliance

To bolster national capabilities, Joshi stressed the importance of India enhancing its self-reliance in the pharmaceutical sector. He noted that sustained support for domestic manufacturing, particularly through the Production Linked Incentive (PLI) scheme, is essential for fostering growth. The PLI scheme has shown promising results, indicating that efforts are beginning to bear fruit.

He added that the Indian government must focus on establishing supportive policies that ensure companies benefitting from the PLI programme continue their investment in domestic capabilities. Creating a secure environment for PLI winners to sustain their growth momentum is vital for the long-term health of the industry.

In conclusion, Joshi’s insights underline a proactive approach towards maintaining and enhancing India’s position in the global pharmaceutical market. As the country navigates a changing international landscape, strategies to increase self-reliance and domestic production are poised to play a crucial role in shaping the future of the pharmaceutical sector.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share